Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer
Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well sapanisertib works in treating patients with lung cancer
that is stage IV or has come back (recurrent) and has a mutation in the NFE2L2, KEAP-1, or
KRAS gene. Damage to these genes may cause the cancer to grow. Sapanisertib may stop this
from happening by blocking enzymes.